CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

fluocinolone acetonide

Last Updated: March 25, 2018
Result type: Reports
Project Number: SR0549-000
Product Line: Reimbursement Review

Generic Name: fluocinolone acetonide

Brand Name: Iluvien

Manufacturer: Knight Therapeutics Inc.

Therapeutic Area: Diabetic macular edema (DME)

Indications: Diabetic macular edema (DME)

Submission Type: Initial

Project Status: Withdrawn

Biosimilar: No

Fee Schedule: Schedule A

Key Milestones2

Call for patient input postedNovember 22, 2017
Patient group input closedJanuary 18, 2018

- No patient input submission received

Submission receivedDecember 21, 2017
Submission accepted for reviewJanuary 12, 2018
Review initiatedJanuary 15, 2018

- Voluntarily withdrawn by the manufacturer on 2018-Mar-23